Leqselvi (deuruxolitinib)
Research Synopsis
- Recent studies indicate that Leqselvi (deuruxolitinib) has shown considerable efficacy in promoting hair regrowth in patients with moderate-to-severe alopecia areata (AA).
- Comparative analyses highlight that deuruxolitinib (12 mg twice daily) provides effective treatment outcomes, especially for patients with higher Severity of Alopecia Tool (SALT) scores.
- Systematic reviews and meta-analyses confirm that Janus kinase (JAK) inhibitors, including deuruxolitinib, outperform other therapies in improving SALT scores among patients with significant hair loss.
- The majority of adverse events reported with deuruxolitinib are mild, though there are concerns about increased risks of infections and specific lab abnormalities.
- A Phase 3 randomized trial (THRIVE-AA1) showed substantial hair regrowth among participants treated with deuruxolitinib compared to placebo, reinforcing its effectiveness.
- Despite promising results, the need for ongoing long-term studies on the safety profile of deuruxolitinib remains a priority due to potential long-term risks associated with JAK inhibitors.
- Research indicates that deuruxolitinib is well-tolerated, but concerns about side effects like hypercholesterolemia and acne have been documented.
- Overall, deuruxolitinib emerges as a significant advancement in the treatment of alopecia areata, aligning with contemporary trends toward targeted therapy for autoimmune conditions.
- As JAK inhibitors gain traction, they highlight an urgent need for tailored treatment strategies and thorough patient monitoring during and after therapy.
- The evolving landscape of alopecia areata management emphasizes the importance of evidence-based approaches and patient-specific considerations in treatment planning.
Leqselvi (deuruxolitinib)
Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.
London, UK
2 hours ago
1 Received
- This study aimed to evaluate the effectiveness and safety of Janus kinase inhibitors for treating alopecia areata, utilizing changes in the Severity of Alopecia Tool (SALT) score as the primary measure.
- A systematic review was conducted by analyzing data from Medline, EMBASE, and Cochrane Library, resulting in 37 relevant studies and a meta-analysis focusing on 5 randomized controlled trials.
- The findings indicate that baricitinib (4 mg daily) is particularly effective for patients with significant hair loss (≥50% scalp loss), while deuruxolitinib (12 mg twice daily) shows the best results for patients with a higher SALT score, suggesting both drugs could be effective with treatment response varying by
$100 - $150
Hourly Rate
Adverse events in patients treated with Jak-inhibitors for alopecia areata: A systematic review.
London, UK
2 hours ago
1 Received
- Recent studies highlight the effectiveness of JAK-inhibitors (JAK-I) for treating alopecia areata (AA), but their safety in patients is still under-researched.
- A systematic review conducted in August 2022 analyzed data from 28 studies involving 1,719 patients to evaluate the adverse events (AEs) linked to six different JAK-I medications.
- Most AEs were mild, with a low withdrawal rate due to side effects; however, laboratory abnormalities and increased infection rates were noted, along with isolated severe cases, but no fatalities were reported.
$100 - $150
Hourly Rate
Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
London, UK
2 hours ago
1 Received
- Management of moderate-to-severe alopecia areata (AA) is challenging due to few safe long-term treatment options available, but newer therapies show promise for hair regrowth with fewer side effects.
- This article reviews newer treatment agents, specifically Janus kinase (JAK) inhibitors, biologics, and phosphodiesterase-4 (PDE-4) inhibitors, by analyzing data from 12 randomized controlled trials that used the Severity of Alopecia Tool score.
- Current findings indicate that oral JAK inhibitors, particularly baricitinib, are effective for significant hair regrowth and have received FDA approval, whereas PDE-4 inhibitors and biologics show limited success, prompting further studies to evaluate their long-term effectiveness.
$100 - $150
Hourly Rate
Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
London, UK
2 hours ago
1 Received
- Janus kinase (JAK) inhibitors show promise as a treatment for alopecia areata, but concerns regarding their safety arise due to differences between this patient group and those with rheumatoid arthritis from whom safety data are largely drawn.* -
- A systematic review analyzed data from 36 studies to identify the safety profile of various JAK inhibitors, highlighting the frequency of adverse events such as hypercholesterolemia, headache, and acne.* -
- Headache and acne were the most common side effects noted, with varying odds ratios for upper respiratory infections among the different JAK inhibitors assessed.*
$100 - $150
Hourly Rate
Overview of alopecia areata for managed care and payer stakeholders in the United States.
London, UK
2 hours ago
1 Received
- - Alopecia areata (AA) is an autoimmune condition that leads to non-scarring hair loss and significantly affects patients' quality of life, often leading to economic burdens and increased prevalence of psychiatric conditions and other health issues.
- - Current treatment options mainly include corticosteroids and emerging therapies like JAK inhibitors, which specifically target the underlying immune response, though more reliable data on treatment effectiveness is still needed.
- - A new tool called the Alopecia Areata Severity Scale has been developed to evaluate the severity of the disease, aiming to provide a more comprehensive approach to managing AA and informing healthcare decisions.
$100 - $150
Hourly Rate
Janus kinase inhibitors for alopecia areata.
London, UK
2 hours ago
1 Received
- Janus kinase (JAK) inhibitors represent a breakthrough in treating moderate-to-severe alopecia areata (AA), a condition that was previously difficult to manage.
- The document discusses the evolution of AA treatment, focusing on the effectiveness and rationale behind using JAK inhibitors.
- It also reviews phase 3 clinical trial results, highlights differences among various JAK inhibitors, and addresses safety and patient selection factors.
$100 - $150
Hourly Rate
The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials.
London, UK
2 hours ago
1 Received
- - Recent therapies for alopecia areata (AA) include Janus kinase (JAK) inhibitors, biologics, and phosphodiesterase-4 (PDE-4) inhibitors, but their effectiveness is not well understood.
- - A systematic review of randomized trials using the Severity of Alopecia Tool (SALT) revealed that JAK inhibitors like baricitinib and ruxolitinib show the highest chances of improving SALT scores, while dupilumab and apremilast are less effective.
- - The study found that oral JAK inhibitors had fewer discontinuations due to side effects compared to dupilumab and apremilast, highlighting the need for further high-quality trials to compare these treatments comprehensively
$100 - $150
Hourly Rate
Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis.
London, UK
2 hours ago
1 Received
- Janus kinase (JAK) inhibitors are becoming popular for treating skin conditions, but there's growing concern about acne as a side effect, which this study aimed to analyze.
- The researchers reviewed multiple phase 2 and 3 clinical trials to assess the incidence of acne in patients taking JAK inhibitors, finding 25 studies with over 10,000 participants.
- Results indicated that JAK inhibitors significantly increase the risk of developing acne, especially those targeting JAK1, with specific drugs showing particularly higher odds of causing this side effect.
$100 - $150
Hourly Rate
Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
London, UK
2 hours ago
1 Received
- * Ongoing studies are exploring Janus kinase (JAK) inhibitors, a new class of drugs, for treating AA, highlighting the need for accurate diagnosis and evaluation before and during treatment.
- * This review updates progress in understanding AA from extensive research published between July 2016 and December 2022, focusing on diagnosis, treatment, and the safety and effectiveness of JAK inhibitors and how they work.
$100 - $150
Hourly Rate
Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis.
London, UK
2 hours ago
1 Received
- - We conducted a Bayesian network meta-analysis on 13 trials with 3,613 patients to evaluate the efficacy and safety of new JAK inhibitors for treating moderate-to-severe alopecia areata, finding that brepocitinib 30mg was the most effective in improving SALT scores.
- - Deuruxolitinib 12mg showed strong effectiveness for severe cases, but it also had a higher likelihood of causing adverse events, while ritlecitinib 50mg appeared to balance safety and efficacy better among high-dose oral options.
- - The study highlights a need for more extensive head-to-head trials over longer periods to validate these findings and further assess the long-term safety of these treatments for alopecia
$100 - $150
Hourly Rate
Novel investigational drugs for alopecia areata and future perspectives.
London, UK
2 hours ago
1 Received
- Alopecia areata (AA) is an autoimmune condition that leads to hair loss without scarring, and a poor prognosis is linked to chronic cases, which can affect mental health and quality of life.
- Treatment options for AA were limited until recently, with two Janus Kinase (JAK) inhibitors now approved to help manage chronic cases.
- New research supports the efficacy of JAK inhibitors, yet concerns about long-term use and potential risks require careful consideration, emphasizing the importance of early treatment intervention.
$100 - $150
Hourly Rate
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
London, UK
2 hours ago
1 Received
- Alopecia areata (AA) is a hair loss disorder that significantly affects quality of life, and studies have shown that the JAK inhibitor deuruxolitinib can promote hair regrowth in affected individuals.
- A Phase 3 trial tested deuruxolitinib in adults aged 18-65 with severe hair loss, finding that a significant percentage of patients experienced notable improvements in hair regrowth compared to a placebo.
- Although the treatment was generally well-tolerated with mostly mild side effects, further research is needed to assess long-term safety and the effects of stopping the treatment.
$100 - $150
Hourly Rate